Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Biomarkers in Major Depression
NCT02165449Phase 1Completed
- Sponsor
- University of California, Los Angeles
- Start
- Jun 2014
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by University of California, Los Angeles. Primary endpoint: Hamilton Depression Rating Scale at 5 weeks. Started Jun 2014; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02165449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02165449.